Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Expert opinion on NSCLC small specimen biomarker testing - Part 2: Analysis, reporting, and quality assessment.

Virchows Archiv : an international journal of pathology - 1 Sept 2022

Penault-Llorca Frédérique, Kerr Keith M, Garrido Pilar, Thunnissen Erik, Dequeker Elisabeth, Normanno Nicola, Patton Simon J, Fairley Jenni, Kapp Joshua, de Ridder Daniëlle, Ryška Aleš, Moch Holger

Abstract excerpt

The diagnostic work-up for non-small cell lung cancer (NSCLC) requires biomarker testing to guide therapy choices. This article is the second of a two-part series. In Part 1, we summarised evidence-based recommendations for obtaining and processing small specimen samples (i.e. pre-analytical steps) from patients with advanced NSCLC. Here, in Part 2, we summarise evidence-based recommendations relating to...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Biomarkers
Share to Carcinoma, Non-Small-Cell Lung

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to High-Throughput Nucleotide Sequencing

Share to Lung Neoplasms

Share to Mutation

Source

Open in PubMed Open full text

Identifiers

PMID: 35857103
DOI: 10.1007/s00428-022-03344-1
PMCID: PMC9297263

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Expert opinion on NSCLC small specimen biomarker testing - Part 2: Analysis, reporting, and quality assessment.PMID 35857103Read ↗

Challenges and Limitations in Molecular Testing of Resected Non-Small Cell Lung Cancer SpecimensSemantic proximity Read ↗

Recommendations for reporting tissue and circulating tumour (ct)DNA next-generation sequencing results in non-small cell lung cancerSemantic proximity Read ↗

Lung cancer cytology and small biopsy specimens: diagnosis, predictive biomarker testing, acquisition, triage, and management.Semantic proximity Read ↗

Different Liquid Biopsies for the Management of Non-Small Cell Lung Cancer in the Mutational Oncology Era.Semantic proximity Read ↗

The emerging roles of NGS-based liquid biopsy in non-small cell lung cancerSemantic proximity Read ↗

Current and future trends in non-small cell lung cancer biomarker testing: The American experience.Semantic proximity Read ↗

Standardized and simplified reporting of next-generation sequencing results in advanced non-small-cell lung cancer: Practical indications from an Italian multidisciplinary group.Semantic proximity Read ↗

Future Perspectives in Detecting EGFR and ALK Gene Alterations in Liquid Biopsies of Patients with NSCLC.Semantic proximity Read ↗

Molecular Pathology of Lung Cancer.Semantic proximity Read ↗

The American Cancer Society National Lung Cancer Roundtable strategic plan: Challenges in clinical guideline recommendations for biomarker testing in lung cancer.Semantic proximity Read ↗

Multiple Biomarker Testing Tissue Consumption and Completion Rates With Single-gene Tests and Investigational Use of Oncomine Dx Target Test for Advanced Non–Small-cell Lung Cancer: A Single-center AnalysisSemantic proximity Read ↗

An update on liquid biopsy analysis for diagnostic and monitoring applications in non-small cell lung cancer.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.